Table 2
Number of (potentially) pathogenic variants in the various specimens
| Ovarian cancer patients (n=29) | ||||
| (Potentially) pathogenic variant |
Self-sample
(n=27) |
Pap smear
(n=26) |
Pipelle
(n=23) |
Surgical sample
(n=29) |
| TP53 | 2 (7) | 6 (19) | 2 (9) | 17 (59) |
| PIK3CA | 3 (11) | 5 (15) | 4 (17) | 6 (21) |
| CTNNB1 | 0 | 1 (4) | 0 | 4 (14) |
| PTEN | 0 | 1 (4) | 1 (4) | 3 (10) |
| KRAS | 0 | 1 (4) | 2 (9) | 2 (7) |
| ARID1A | 2 (7) | 1 (4) | 1 (4) | 1 (3) |
| MTOR | 0 | 0 | 0 | 1 (3) |
| POLE | 0 | 0 | 0 | 0 |
| Total number of pathogenic variants | 7 | 15 | 10 | 34 |
| Patients without a pathogenic variant | 21 (78) | 16 (62) | 16 (70) | 5 (17) |
| Control patients (n=32) | ||||
| (Potentially) pathogenic variant |
Self-sample
(n=31) |
Pap smear
(n=32) |
Pipelle
(n=32) |
Surgical sample
(n=31) |
| TP53 | 0 | 0 | 0 | 0 |
| PIK3CA | 0 | 2 (6) | 2 (6) | 0 |
| CTNNB1 | 0 | 0 | 0 | 0 |
| PTEN | 0 | 0 | 0 | 0 |
| KRAS | 0 | 0 | 0 | 2 (6) |
| ARID1A | 1 (3) | 0 | 0 | 0 |
| MTOR | 0 | 0 | 0 | 0 |
| POLE | 0 | 0 | 0 | 0 |
| Total number of pathogenic variants | ||||
| Patients without a pathogenic variant | 30 (97) | 30 (94) | 30 (94) | 29 (94) |
Values are presented as number of pathogenic variants (% of patients).
Percentages may total >100% as one patient can have multiple variants.